Supplementary Material to Di Nisio et al. “Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists” (Thromb Haemost 2016; 115.2)

Suppl. Figure 1. Association between weight and risk of major bleeding in the first 3 weeks of anticoagulant treatment

![Graph depicting the association between weight and risk of major bleeding](image-url)
Suppl. Figure 2. Association between hemoglobin and risk of major bleeding among males and females after the first 3 weeks of anticoagulant treatment.
Suppl. Figure 3. Association between hemoglobin and risk of major bleeding among males and females during the whole period of anticoagulant treatment.
Suppl. Figure 4. Association between weight and risk of major bleeding during the whole period of anticoagulant treatment

All treatment-emergent major bleedings - Cumulative incidence at Day 180 for weight from the univariate Cox proportional hazard model

- Enoxaparin/VKA
- Rivaroxaban

Cumulative incidence

Weight (kg)